Clinical trial
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+)…
NCT00440622 · Hellenic Oncology Research Group, Other · Terminated
Key facts
| NCT number | NCT00440622 |
|---|---|
| Title | Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients |
| Official title | A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Herceptin, Capecitabine (Xeloda) |
| Enrollment | 90 |
| Start date | Apr 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 27, 2007 |
| Last update posted | Feb 13, 2013 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: